Psychiatric Problems in Children and Adolescents Infected With HIV at Birth

This study has been completed.
Sponsor:
Collaborators:
Information provided by:
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00100542
First received: January 3, 2005
Last updated: January 20, 2011
Last verified: January 2011
  Purpose

The purpose of this study is to determine whether HIV and anti-HIV drugs cause mental health problems or make mental health problems worse in children and adolescents who were infected with HIV at birth.


Condition Intervention
HIV Infections
Mental Disorders
Behavioral: Psychiatric interviews

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Psychiatric Co-Morbidity in Perinatally HIV-Infected Children and Adolescents

Resource links provided by NLM:


Further study details as provided by International Maternal Pediatric Adolescent AIDS Clinical Trials Group:

Estimated Enrollment: 800
Study Start Date: April 2005
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
All HIV infected and uninfected participants and their caregivers.
Behavioral: Psychiatric interviews
Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.

Detailed Description:

Research has shown that HIV is able to penetrate the blood-brain barrier and may significantly affect the central nervous system (CNS). Although the effects of HIV on the CNS are not fully understood, there is growing evidence that the effects are psychosocial in nature; HIV infected children experience higher rates of psychiatric symptoms and hospitalizations than their uninfected counterparts. Confounding the HIV CNS relationship is evidence suggesting that the CNS effects of HIV may also be related to antiretroviral treatment. This study will examine the rates and severity of psychiatric symptoms in both HIV infected and uninfected children and adolescents. In addition, this study will determine the relationship between duration of antiretroviral treatment and psychiatric symptoms.

No treatment will be given as part of this study. The study will last for 96 weeks and be divided into two parts. In Part 1, HIV infected and uninfected participants and their caregivers will complete a series of measures and questionnaires regarding mental health, pain, and adherence to treatment. In Part 2, all participants and their caregivers will complete a subset of the original measures at Weeks 48 and 96. This follow-up part of the study will assess any long-term changes in psychiatric symptoms. In addition, a subset of HIV infected and uninfected participants and their caregivers will take part in psychiatric interviews at specified study sites. A portion of these interviews will be audio-taped.

  Eligibility

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Children and their caregivers from specific clinics.

Criteria

Inclusion Criteria for HIV Infected Participants:

  • Acquired HIV through mother-to-child transmission

Inclusion Criteria for HIV Uninfected Participants:

  • HIV uninfected

Inclusion Criteria for All Participants:

  • Living with same parent or primary caregiver for at least 12 months prior to study screening
  • Willing and able to provide consent or assent

Exclusion Criteria for HIV Infected Participants:

  • Acquired HIV through adult high-risk behavior, blood transfusion, or abuse

Exclusion Criteria for All Participants:

  • IQ of 69 or lower, for participants whose primary language is English. More information on this criterion can be found in the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00100542

  Show 32 Study Locations
Sponsors and Collaborators
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Investigators
Study Chair: Sharon Nachman, MD Department of Pediatrics, Stony Brook University
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Wende Levy, IMPAACT
ClinicalTrials.gov Identifier: NCT00100542     History of Changes
Other Study ID Numbers: PACTG P1055, U01AI068632
Study First Received: January 3, 2005
Last Updated: January 20, 2011
Health Authority: United States: Federal Government

Keywords provided by International Maternal Pediatric Adolescent AIDS Clinical Trials Group:
Treatment Experienced
Treatment Naive
Psychopathology
Anti-Retroviral Agents
Child
Adolescent

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Mental Disorders
Psychotic Disorders
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Schizophrenia and Disorders with Psychotic Features
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 20, 2014